NORTHWELL HEALTH

Evernorth Health Services, a subsidiary of The Cigna Group, announced a $3.5 billion preferred stock investment in Shields Health Solutions to strengthen specialty pharmacy management capabilities.

TAS-102 demonstrated significant ctDNA clearance rates of 47% at 3 months and 36% at 6 months in colorectal cancer patients with minimal residual disease, compared to only 6.7% in the synthetic control cohort.

A multidisciplinary expert panel from leading pulmonology organizations concluded that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) provides safer tissue sampling than percutaneous approaches while maintaining adequate sample quality for biomarker testing.

The FDA has granted 510(k) clearance to an updated version of the Philips UroNav System, featuring advanced annotation workflow for enhanced precision in minimally invasive prostate cancer focal therapy procedures.

SurgiVance Inc. received a $2,245,000 National Cancer Institute Small Business Innovation Research Direct-to-Phase II grant to commercialize its "pathology lab-in-a-box" technology.

A large retrospective study of over 161,000 cancer patients across four major U.S. health systems found that COVID-19 booster vaccines reduced hospitalizations and ICU admissions by 29%.

A peer-reviewed narrative review published in Cureus journal highlights the therapeutic potential of long-acting synthetic cannabidiol (CBD) for chronic pain management as a non-opioid alternative.

Healthcare experts at the 2025 Methods Summit stressed that research must align with patient preferences beyond traditional clinical metrics to deliver true value.

Feinstein Institutes researchers have discovered how the vagus nerve detects and communicates specific inflammatory signals to the brain, revealing a complex encoding system for immune information.

• Real-world data presented at AUA 2025 shows the CVAC System achieves significant kidney stone volume reduction of up to 99% in most patients, with one study reporting a median clearance rate of 96.4%. • The CVAC System demonstrated superior performance compared to flexible and navigable ureteric access sheath (FANS), removing significantly more absolute stone volume while maintaining consistently low intrarenal pressure. • Multiple studies using Quantitative Stone Analysis Software (QSAS) validate stone volume as a more precise and clinically meaningful measure for assessing kidney stone treatment outcomes.